Evidence map›Paper›PMID 19445684›Full record

ArticleBMC biotechnology2009

Fluorescent labeling of NASBA amplified tmRNA molecules for microarray applications.

Ott Scheler, Barry Glynn, Sven Parkel, Priit Palta, Kadri Toome, Lauris Kaplinski, Maido Remm, Majella Maher, Ants Kurg

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ott SchelerDepartment of Biotechnology, Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia. ott.scheler@ut.ee
Barry Glynn
Sven Parkel
Priit Palta
Kadri Toome
Lauris Kaplinski
Maido Remm
Majella Maher
Ants Kurg
Estonian Biocentre · EEOllscoil na Gaillimhe – University of Galway · IEUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHere we present a novel promising microbial diagnostic method that combines the sensitivity of Nucleic Acid Sequence Based Amplification (NASBA) with the high information content of microarray technology for the detection of bacterial tmRNA molecules. The NASBA protocol was modified to include aminoallyl-UTP (aaUTP) molecules that were incorporated into nascent RNA during the NASBA reaction. Post-amplification labeling with fluorescent dye was carried out subsequently and tmRNA hybridization signal intensities were measured using microarray technology. Significant optimization of the labeled NASBA protocol was required to maintain the required sensitivity of the reactions.

resultsTwo different aaUTP salts were evaluated and optimum final concentrations were identified for both. The final 2 mM concentration of aaUTP Li-salt in NASBA reaction resulted in highest microarray signals overall, being twice as high as the strongest signals with 1 mM aaUTP Na-salt.

conclusionWe have successfully demonstrated efficient combination of NASBA amplification technology with microarray based hybridization detection. The method is applicative for many different areas of microbial diagnostics including environmental monitoring, bio threat detection, industrial process monitoring and clinical microbiology.

Indexed as

Fluorescent DyesOligonucleotide Array Sequence AnalysisRNA, BacterialSelf-Sustained Sequence ReplicationSensitivity and SpecificityStreptococcus pneumoniaeUridine TriphosphateFluorescent DyesRNA, BacterialtmRNAUridine Triphosphate

Identifiers

PMID19445684
PMCPMC2685129
OpenAlexW2108740912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.